Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Jiangsu HengRui Medicine Co., Ltd.
Shukui Qin; Stephen L Chan; Shanzhi Gu; Yuxian Bai; Zhenggang Ren; Xiaoyan Lin; Zhendong Chen; Weidong Jia; Yongdong Jin; Yabing Guo; Xiaohua Hu; Zhiqiang Meng; Jun Liang; Ying Cheng; Jianping Xiong; Hong Ren; Fang Yang; Wei Li; Yajin Chen; Yong Zeng; Alexander Sultanbaev; Monika Pazgan-Simon; Margaryta Pisetska; Davide Melisi; Dmitriy Ponomarenko; Yurii Osypchuk; Ivan Sinielnikov; Tsai-Sheng Yang; Xiao Liang; Chunxia Chen; Linna Wang; Ann-Lii Cheng; Ahmed Kaseb; Arndt Vogel; CARES-310 Study Group